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Background: Cardiovascular disease, endothelial dysfunction, and oxidative stress are common complications among
patients with type 2 diabetes (T2DM). In addition to the average blood glucose concentration, glycemic variability may be
an important factor for the development of chronic diabetes complications. Patients with T2DM are treated with various
types of oral glucose-lowering drugs. Exercise is considered to benefit the health of both healthy and unhealthy
individuals, which has been confirmed by a number of scientific research studies in which the participants’ health
improved. Our general aim in this study will be to evaluate glucose variability after submaximal exercise test in patients
receiving treatment with either vildagliptin or glibenclamide. The specific aims of this study are to evaluate the oxidative
stress, endothelial function, and metabolic and cardiovascular responses to exercise under treatment with vildagliptin or
glibenclamide. All these responses are important in patients with T2DM.
Methods/Design: This study is a PROBE (Prospective, Randomized, Open-label, Blinded-Endpoint) design clinical trial.
The estimated sample needed is 20 patients with T2DM. In addition to the routine treatment (metformin), patients will
receive a second drug orally for 12 weeks: the METV group will receive metformin plus vildagliptin (50 mg twice daily), and
the METG group will receive metformin plus glibenclamide (5 to 10 mg twice daily.). Before and after intervention,
evaluation of glycemic variability, endothelial function, oxidative stress, and metabolic and cardiovascular response will be
performed at rest, during and after a submaximal exercise test (30 minutes, with an intensity based at 10% under the heart
rate at the second threshold).
Discussion: In addition to drug treatment, exercise is recommended for treatment of glycemic control in patients with
T2DM, especially for its beneficial effects on blood glucose and HbA1c. Few studies have determined the effects of the
association between exercise and oral glucose-lowering drugs. The study will be conducted to assess the metabolic
and cardiovascular responses at rest, and during and after submaximal exercise in patients receiving one of two oral
glucose-lowering drugs (vildagliptin or glibenclamide).
Trial registration: ClinicalTrials.gov Identifier: NCT01867502 study release date: May-17-2013.
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Cardiovascular disease is the main cause of mortality
among people with type 2 diabetes mellitus (T2DM)
[1,2]. Accelerated atherosclerosis in these patients is
preceded by endothelial dysfunction, inflammatory
burden, and increased lipid peroxidation, all leading to
enhanced macrophage foam cell formation [2]. In
addition to the average blood glucose concentration,
acute glycemic fluctuations from peaks to nadirs (glu-
cose variability) may be involved in the development of
diabetic complications [3], as they contribute to the
generation of excessive protein glycation and oxidative
stress [4]. High glucose variability has been shown to be
associated with endothelial dysfunction in patients with
T2DM and optimal metabolic control [5]. Currently, the
mean amplitude of glycemic excursion (MAGE) is one
of the most used methods for detecting significant
swings in glycemia [6], but other tools may be useful to
identify disturbances in glucose variability [7].
Some current treatments for T2DM have already been
tested concerning their possible effects in reducing glu-
cose variability as well as reducing glycated hemoglobin
(HbA1c) [8]. Exercise, which is one of the cornerstones
of treatment for hyperglycemia in T2DM because of its
beneficial effect on HbA1c [9], was recently shown to
reduce glucose variability in addition to its acute effects
on reducing glucose levels [7]. Vildagliptin and sitaglip-
tin are two drugs that were recently evaluated in a study
focusing on possible differences in daily glucose fluctua-
tions in patients with T2DM inadequately controlled
with metformin, and it showed that vildagliptin wasTable 1 Measures evaluated in order to reach the outcomes
Time point Data collection M
At rest Continuous glucose monitoring system Gl
Vascular Doppler ultrasound Flo
Blood sampling Gl
GL
Impedance cardiography and
electrocardiogram
Ca
24 hour urine F2
cr
During submaximal exercise
tests
Continuous glucose monitoring system Gl
Impedance cardiography and
electrocardiogram
aC
Blood sampling aG
After submaximal exercise
tests
Continuous glucose monitoring system Gl
Impedance cardiography and
electrocardiogram
ab
Ambulatory blood pressure monitoring 24
Blood sampling ab
GLP-1, glucagon-like peptide 1; HbA1c, glycated hemoglobin. a0, 15, and 30 minutemore effective in flattening acute glucose fluctuations
over a day [8]. Moreover, acarbose was superior to glib-
enclamide in reducing MAGE. Therefore, aside from
their absolute glucose-lowering effect, it is evident that
other effects of different anti-diabetic agents might also
be different [10].
The present study will be conducted to test the hypoth-
esis that in combination with metformin, vildagliptin may
produce a greater improvement in glucose variability after
a submaximal exercise test, compared with glibenclamide.
Our general aim will be to evaluate glucose variability
after the submaximal exercise test in patients receiving
treatment with vildagliptin or glibenclamide. The specific
aims of this study are to evaluate the oxidative stress,
endothelial function, and metabolic and cardiovascular re-
sponses to exercise in patients treated with vildagliptin or
glibenclamide.Methods/Design
Research design
This study is a PROBE (Prospective, Randomized, Open-
label, Blinded-Endpoint) design clinical trial.Outcomes
The primary outcome will be glucose variability evaluation,
as evaluated by conventional and non-conventional me-
thods. Secondary outcomes will include oxidative stress,
endothelial function, and metabolic and cardiovascular
responses to exercise. Table 1 shows the measures that will
be evaluate to reach the outcomes.easure Outcomes
ucose values Glucose variability
w-mediated dilatation Endothelial function
ucagon, glucose, HbA1c, insulin and
P-1
Metabolic responses
rdiac output, heart rate Cardiovascular response
isoprostane 8-isoprostaglandin F2α/
eatinine
Oxidative stress
ucose values Glucose variability
ardiac output, heart rate Cardiovascular response to
exercise
lucagon, glucose, insulin, and GLP-1 Metabolic responses
ucose values Glucose variability
Cardiac output, heart rate Cardiovascular response to
exercise
hour blood pressure variability
Glucagon, glucose, insulin and GLP-1 Metabolic responses
s; ab60 minutes after exercise.
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According to data reported by Marfella et al. [8], a total
sample size of 20 patients (allowing for a dropout rate of
10%) should allow detection of a difference between groups
with MAGE levels (mean ± SD) of 25.0 ± 16 mg/dl at week
12, assuming statistical power of 90%, and a significance
level of 1% (two-sided, two-sample t-test).
Inclusion and exclusion criteria
The inclusion criteria will be age older than 18 years, pres-
ence of T2DM, use of metformin, recent HbA1c between
7.5% and 10%, and no involvement in regular physical
activity.
The exclusion criteria will be: current smoking; body
mass index (BMI) >40 kg/m2; presence of proliferative
diabetic retinopathy, ischemic heart disease, peripheral
vascular disease, cognitive decline or dementia, neuro-
logical events, severe depression, or current diagnosed
cancer; lactose intolerance; hepatic enzyme levels three-
fold higher than the reference values; glomerular filtra-
tion rate lower than 60 ml/min; blood pressure (BP)
over 180/100 mmHg at rest; use of analgesic or anti-
inflammatory drugs during the week of the study; use of
insulin; and untreated thyroid dysfunction.
Eligibility assessment and follow-up visits
Eligibility and exclusion criteria will take place in two
visits, and will be assessed by medical records, patient
interviews and laboratory tests.
A physician will be responsible for the cardiovascular as-
sessment, using the American Heart Association guidelines
[11]. The same physician will assess the presence of periph-
eral vascular disease using the ankle brachial index [12].
Two follow-up consultations will take place after 4
and 8 weeks of treatment to measure BP, heart rate, and
body weight.
Randomization
The randomization sequence will be generated by the R
software (v2.12.1 Vienna, Austria, 2011), with a block
size of five. Randomization to the metformin plus vilda-
gliptin group (METV) or the metformin plus glibencla-
mide group (METG) will be performed by a researcher
responsible only for this task, who will not participate in
the recruitment, assessment, or intervention phases of
the study.
Data collection
Eligible patients will initially perform a maximum effort
test, and 48 hours later, they will begin the study proto-
col, as follows:
 Day 1: Begin 24-hour urinary collection, perform
vascular Doppler ultrasound to evaluate endothelialfunction, and then insert glucose sensor subcutane-
ously to begin continuous glucose monitoring sys-
tem (CGMS) evaluation.
 Day 2: End the 24-hour urinary collection, carry out
the submaximal exercise test (with blood collection
at baseline, 15, and 30 minutes into the session, and
60 minutes after recovery). Assess heart rate vari-
ability 10 minutes before and after the submaximal
exercise test, and begin 24 h ambulatory blood pres-
sure monitoring (ABPM).
 Day 3: Removal of the glucose sensor; end 24 h
ABPM. Randomization.
This same protocol will be repeated at the end of the
12-week treatment with vildagliptin or glibenclamide.
The experimental sessions will occur at the Exercise
Pathophysiology Research Laboratory, Hospital de Clíni-
cas de Porto Alegre (LaFiEx-HCPA), maintaining the
ambient temperature at between 20 and 22°C.
Patients will be asked to follow their habitual diet dur-
ing the 3 days of protocol. To carry out the submaximal
exercise test they will go to LaFiEx-HCPA in a fasted
state. Patients will record detailed food intake in diaries
across the 3 days of CGMS use. The dietary assessment
will be performed using the software DietWin (DietWin,
Porto Alegre, Brazil). In addition, participants will be
instructed to avoid intense activities and not to consume
caffeinated beverages on the day before the dietary as-
sessment, in order to exclude any residual effect before
and after the effort test. The submaximal exercise test
will occur after a standard breakfast (500 kcal; 60%
carbohydrate, 30% fat and 10% protein). During the drug
treatment period (12 weeks) patients will not follow any
kind of physical exercise program. The flow diagram of
the study design is shown in Figure 1.
Study intervention
The METV group will receive 50 mg of vildagliptin orally
twice a day. The METG group will receive glibenclamide 5
mg orally once per day during the first week of the study,
then in the second week, the dose will be increased to 10
mg a day (5 mg twice a day). The dose may be adjusted to
reach a target pre-prandial capillary plasma glucose level of
70 to 130 mg/dl without frequent or severe hypoglycemia,
up to the maximum dose allowed (20 mg a day). Patients
will be instructed to measure capillary glycemia using a glu-
cose monitor (Accu-Check Performa; Roche Diagnostics,
Mannheim, Germany) twice a week and at any time if they
believe they have symptoms of hypoglycemia. These mea-
sured values will be recorded at the follow-up visits or
passed on to the researchers in a phone call when two con-
secutive values lower than 70 mg/dl occur. This procedure
will be explained at the beginning of the study. Medication
adjustments will be guided by the researcher coordinator
Figure 1 Flow diagram of the study design. # The submaximal exercise test (SET) will occur on the day 2 of a 3-day period of tests. METV group: 12
week s of treatment with vildagliptin added to metformin; METG group: 12 weeks of treatment with glibenclamide added to metformin. *500 to 2000
mg/day according to tolerance; **50 mg twice daily; ***10 to 20 mg twice daily. ABPM: ambulatory blood pressure monitoring, CO: cardiac output, CGMS:
continuous glucose monitoring system; BS: blood sample; HRV: heart rate variability, MET: maximal exercise test. †Metabolic evaluation: glucose, HbA1c,
insulin, glucagon-like peptide 1 (GLP-1).
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Maximal exercise and submaximal exercise tests
A maximal exercise test will be performed to determine
peak oxygen consumption (VO2peak) and ventilatory
thresholds. Exercise capacity will be defined by a pro-
gressive maximal exercise test performed on a cycle erg-
ometer, with increments of 20 W/min. The test will be
carried out at 60 rpm until exhaustion. Oxygen con-
sumption (VO2) and carbon dioxide production (VCO2)
will be determined by averaging the gas exchange by a
computerized system (Oxycon Delta; VIASYS Health-
care GmbH, Jaeger, Germany). The test will be finished
when the individual is unable to maintain the 60 rpm
speed. The VO2 peak is defined as the VO2 peak reached
at the end of this exercise [13]. Heart rate will be con-
tinuously monitored by a 12-lead electrocardiogram
(Nihon Kohden Corp., Tokyo, Japan).
The ventilatory thresholds will be determined at the
breakpoint between the highest point of the CO2 produc-
tion curve and VO2 (V slope), or at the point where the
curves of ventilatory equivalent for oxygen (VE/VO2) and
end tidal oxygen (PETO2) reach their respective minimum
values and begin to increase. The respiratory compensation
point will be determined when the levels of VE/VO2 reach
their minimum values before they start to rise, and when
PETCO2 reach their maximum values before these begin to
decline [14].
The submaximal exercise tests are designed to simulate a
typical aerobic exercise session on a cycle ergometer. The
test will last 30 minutes, with an intensity based at 10%
under the heart rate at the second threshold, which will be
obtained in advance. Each patient will undergo two sub-
maximal exercise tests, which will be performed before and
after intervention. Before the test, at 15 minutes, at the end(30 minutes) and 60 minutes after each submaximal exer-
cise test, 20 ml of blood will be collected and the variables
described later will be measured, with the exception of
HbA1c (measured just before exercise). The cardiovascular
responses will be obtained as described below.
Glucose variability evaluation
CGMS will be utilized for this evaluation. Subjects will
be admitted to the laboratory in the morning at approxi-
mately 08.00 hours, 24 hours before the exercise session,
when the glucose sensor (Sof-SensorTM; Medtronic
Mini-Med Inc., Northridge, CA, USA) will be inserted
subcutaneously. The sensor is a glucose oxidase-based
platinum electrode that is inserted through a needle into
the subcutaneous tissue of the anterior abdominal wall,
using a spring-loaded device (Senserter, Medtronic
Mini-Med Inc.).
Glucose oxidase catalyzes the oxidation of glucose in
the interstitial fluid, which generates an electrical
current. The current is carried by a cable to a pager-
sized monitor that analyzes the data every 10 seconds
and reports average values every 5 minutes, to give a
total of 288 readings per day. Glucose profiles will be
collected on the day before (day 1), the day of (day 2),
and the day after (day 3) the submaximal exercise test.
Sensor readings will be calibrated with a glucose moni-
tor (Accu-Check Performa; Roche Diagnostics) using
four finger-stick blood samples for each 24 hours. Each
sensor will be used continuously for up to 48 hours. All
patients will have been instructed previously about the
operation of the monitor, which includes event registra-
tion for meals, and inserting capillary glucose values for
calibration.
Glucose variability will be assessed from a series of abso-
lute values of glucose, obtained by the CGMS, sampled
every 5 minutes. Each method will be used as reported in
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ability will be evaluated using conventional analysis and
other mathematical methods generally applied to biological
series, here called “non-conventional analysis of glucose
variability.” Conventional analysis of glucose variability will
be constructed from the statistical properties of the series,
to obtain the following indices: MAGE [6], glucose variance
(VAR), glucose coefficient of variation (CV%), and glucose
SD, all normalized by the mean blood glucose in each
period [15,16]. These indices, except MAGE, will be calcu-
lated for every 6 hour block of glucose values to obtain the
measures according to the specific period of the day. The
MAGE index will be calculated for the whole signal (24
hours), and its calculation is based on the differences be-
tween consecutive points, considering those which are
higher than 1SD [16].
Non-conventional analysis of glucose variability will be
conducted using two methods applied to the glucose
series: a linear method based on spectral analysis, and an
integrated non-linear approach to the complexity ana-
lysis, called symbolic analysis. Spectral analysis is a linear
method that allows quantification of the oscillatory com-
ponents from time series by autoregressive models
widely applied for heart rate and arterial pressure series
[17]. Symbolic dynamics relies on the calculation of
Shannon entropy of the distribution of patterns lasting
three measures and the classification of frequent deter-
ministic patterns lasting three measures, and distributes
deterministic patterns of the group into four categories
according to the number and pattern: 1) no variation
(0 V), 2) one variation (1 V), 3) two like variations (2
LV), and 4) two unlike variations (2 UV) [18]. This
method has been fully described and validated previously
to glucose curves [7].
Metabolic evaluation
Peripheral venous blood will be collected into 10 ml vacu-
tainer tubes, and used to perform the blood tests; these
samples will be stored at −20°C. Glucose, HbA1c, insulin,
glucagon, and glucagon-like peptide 1 (GLP-1) will be
assayed.
Oxidative stress evaluation
The 24-hour urinary samples will be collected at visits 1 and
6 and used to evaluate creatinine and 8-isoprostaglandin
F2α (8-isoPGF2α), which is considered a well-recognized
marker of oxidative stress [19]. This isomer will be mea-
sured using a competitive enzyme-linked immunoassay
(ELISA) (Cell Biolabs Inc. San Diego, CA USA).
Cardiovascular evaluation
Cardiac output and heart rate will be measured before
(10 minutes at rest) and during the submaximal exercise
test and after 60 minutes of recovery, using a non-invasive method. The data will be recorded (MP150 sys-
tem; Biopac Santa Barbara, CA, USA) using a general
purpose amplifier module (DA100; Biopac), impedance car-
diography (NICO100C; Biopac) and electrocardiogram
(ECG100C; Biopac), according to methodological guidelines
provided by Sherwood et al. [20].
To assess the cardiovascular autonomic control, heart
rate variability (HRV) analysis will be applied. Pulse in-
tervals (PI) series (tachograms) will be obtained from the
electrocardiography records. Stationary segments (300
beats), coincident in the tachogram, will be selected, and
spectral analysis will be performed using an autoregres-
sive model, which estimates the center frequency and
power of each relevant oscillatory component. The spec-
tral bands for humans are defined as very low frequency
(VLF), for 0.0 to 0.04 Hz, low frequency (LF), for 0.04 to
0.15 Hz, and high frequency (HF) for 0.15 to 0.40 Hz in-
tervals, defined according to previous references [17].
Tachogram spectra will be evaluated quantitatively, and
values of HRV will be obtained, as well as its spectral
components, and will be expressed in absolute (ms2). In
additional, LF and HF bands will be expressed in nor-
malized units (NU), obtained by calculating the power of
LF and HF spectra, and correlating them with the total
power without the VLF component [17].
Of the parameters that can be obtained by spectral
analysis, those distinguished for their physiological sig-
nificance are the LF and HF components, which are
mainly related to sympathetic and parasympathetic car-
diac modulations, respectively. The relationship between
them – the LF/HF index, or sympathetic-vagal balance
[21] – will be evaluated.
Patients will be submitted to a 24 hour ABPM on a
usual work day, using a monitor (model 90207; Space-
labs, Redmond, WA, USA) that will be programmed to
automatically measure BP every 15 minutes during the
day (06.00 to 22.00 hours), and every 20 minutes during
the night (22.00 to 6.00 hours) [22,23]. BP variability will
be assessed from BP behavior in different windows of a
24 hour period, covering both daytime and night-time
periods. The cuff size will be adapted to the circumfer-
ence of the arm of each patient according to the manu-
facturer’s recommendations.
Based on the results of the 24 hour ABPM, the mean
24 hour systolic BP (SBP) and diastolic BP (DBP) will be
calculated for each patient, before and after treatment.
Three different parameters of SBP variability will be cal-
culated: 1) time–rate index (rate of change in SBP over
time in mm Hg/min, defined as the first derivative
values of SBP by time); 2) coefficient of variation of the
24 hour SBP (SD/mean pressure × 100%); and 3) mean
of the SD of the 24 hour SBP. The time–rate index al-
lows the calculation of the sum of angular coefficients,
and aims to measure how fast or how slow SBP values
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will be calculated using the formula,
R ¼ rj j ¼
XN−1
i−1
rij j
N−1
where r is the rate of BP variability over time (consider-
ing the differences between BP measurements at each
time interval) and N is the number of recordings [24]:
Endothelial function evaluation
This analysis will be performed by a high-resolution ultra-
sound of the brachial artery (vascular Doppler), which char-
acterizes the flow-mediated dilatation (FMD). FMD is
expressed by changes in basal diameter in response to the
increased flow and to nitroglycerin, which will be adminis-
tered in a single dose (0.4 mg, sublingual spray). The equip-
ment used will be an HD7XE (Philips, Bothell, WA, USA)
with an HF transducer (3 to 12 MHz; L12-3; Philips) [25].
Ethics and data protection issues
Participation will be voluntary, and will follow the ethical
aspects of confidentiality and data protection. Procedures
will be explained to patients, and information about the
aim, design, associated potential risks and benefits and all
relevant details of the research will be given in the informed
consent form. All patients will have to sign the informed
consent form prior to participating in the study. The data
obtained by the study will be available to the participant
and to any other authorized person, and may be used an-
onymously for academic scientific purposes.
The study was approved by Scientific Committee and
Research Ethical Comission (IRB number 120444) of
Hospital de Clínicas de Porto Alegre (Brazil), which
is part of National Committee of Ethics in Research.
Approval Number: 10662912.3.0000.5327.
Safety assessment
Adverse events (AEs), including serious adverse events
(SAEs) or pregnancies will be collected and included in
the medical reports. The reports containing details of
SAEs or pregnancies will be forwarded to the laboratory
of the respective manufacturer within 24 hours, and to
the health authorities.
To ensure patient safety, the individuals participating
in the research will be monitored for the occurrence of
all AEs after beginning the specific protocol procedures
until 4 weeks after the patient discontinues participation
in the study.
Statistical analysis plan
Data will be analyzed using SPSS software (Statistical
Package for Social Sciences; version 18.0 for Windows,
SPSS Inc., Chicago, USA). The description of values willbe expressed as mean ± SD. The statistical procedures
used will be Student’s t-test for independent samples (in-
tergroup analysis), paired t-test (intragroup analysis),
and analysis of variance (ANOVA) for repeated mea-
sures to compare both groups at different times. A Pear-
son correlation will be performed between measures of
glucose variability and 8-isoPGF2α/crn. The statistical
power will be 90%, and the accepted level of significance
will be P < 0.01.
Discussion
Several anti-diabetic agents are available for T2DM treat-
ment. These treatments differ in their mechanism of drug
action and their long-term outcomes. In addition to these,
non-pharmacological treatments are important, especially
exercise, as it is a major tool to achieve target blood glucose
and HbA1c. Non-glucose beneficial effects can also be ob-
tained. The many studies reporting the effects of the associ-
ation between exercise and oral glucose-lowering drugs
usually focus on attaining better metabolic control. This
study will be conducted to report the glucose variability
and cardiovascular responses at rest, during and after sub-
maximal exercise under two oral glucose-lowering drugs
(vildagliptin versus glibenclamide).
Trial status
Not yet recruiting. Enrolment will begin in April 2014.
Each patient will have 10 visits to the hospital, and total
data collection time will be 16 months.
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